Two manufacturers. Same revenue. Same assets. One funded its growth without friction. The other kept running into a ceiling it could not explain. The difference was not the business — it was the structure of the debt: ABL versus cash-flow lending.
The choice between ABL vs. cash-flow lending for manufacturers is rarely a deliberate decision. It is usually inherited — the product a bank brought when the facility was first set up, then carried forward for years without anyone asking whether it still fits. For a profitable manufacturer, the wrong answer is expensive, and the cost does not show up in basis points. It shows up as growth the business could support but the facility will not fund.
- ABL sizes a facility off collateral — receivables and inventory — capped at the borrowing base, not earnings.
- Cash-flow lending sizes off EBITDA: banks at 3–4x, direct lenders at 4–5.5x. For a profitable manufacturer, that is typically far more debt capacity than an ABL line on the same business.
- In 2026, tariff-inflated inventory carrying values sit above appraised liquidation values, so ABL borrowing bases are delivering less than the balance sheet implies.
- The real cost of the wrong structure is growth not funded — an acquisition, a capital project, or owner liquidity the earnings could support.
- A restructure from ABL to cash-flow lending typically runs 30–60 days for a first-time, non-sponsored manufacturer.
How ABL Sizes a Facility — and Where It Caps Out
Asset-based lending sizes off collateral, not earnings. Availability is a borrowing base: an advance rate against eligible receivables, plus an advance rate against eligible inventory (advance rates that, per SFNet benchmarks, are well established for each). It is a clean, efficient product for a business whose constraint is the working-capital cycle — the line breathes as receivables and inventory rise and fall.
The limit is structural. A borrowing base can only lend against the assets on the books today; it cannot lend against where the business is going. A manufacturer whose earnings could comfortably support more debt can still be capped well below that level, simply because the collateral pool is smaller than the opportunity. (Some facilities layer in a FILO loan to stretch availability a step beyond the standard borrowing base — but the ceiling logic is the same.)
2026 has widened that gap. Inventory advances are set against appraised value, not book cost. Where tariffs inflated the carrying cost of imported inputs — and have since largely come off — the appraised liquidation value can sit below that inflated book cost. The result, per ABF Journal’s 2026 manufacturing coverage, is that eligible inventory, and the borrowing base built on it, can deliver less than the balance sheet shows — with the effect largest for manufacturers carrying heavy imported-input inventory.
What Cash-Flow Lending Adds: Debt Capacity
Cash-flow lending sizes off EBITDA, not collateral. The underwriting question is how much debt the earnings can support — so for a profitable manufacturer, the capacity is typically much larger than a borrowing base on the same assets. Bank cash-flow facilities generally run 3–4x Total Debt/EBITDA; non-bank direct lenders run 4–5.5x. The high end of each range is reserved for larger and, ideally, PE-backed credits, so a non-sponsored manufacturer should expect the lower end — closer to 3x from a bank, ~4x from a direct lender (Capstone Partners, Q1 2026).
The difference is not subtle. At 4x on $12MM of EBITDA, the facility is about $48MM. An ABL borrowing base on the same manufacturer’s collateral might produce $15–25MM. Same company; the capacity depends entirely on which product is sizing it.
That capacity is what reaches the things a collateral cap cannot: an acquisition, a capital project, or liquidity for the owner without a sale. It also costs more to carry. Cash-flow lending prices wider than ABL, and it comes with maintenance covenants — most often a fixed-charge coverage ratio, which nearly every middle-market cash-flow deal includes (Proskauer). That ratio measures cash flow against fixed charges, so it effectively sets how much debt the earnings can carry — and higher rates tighten it. A $48MM term loan at SOFR plus 500 bps (SOFR near 3.63%) runs about $4MM a year in interest before principal, and as that number climbs, the same earnings support less debt. The right covenant package is one the business can carry through a full rate cycle, not just at closing.
ABL vs. Cash-Flow Lending for Manufacturers — At a Glance
| Dimension | Asset-Based Lending (ABL) | Cash-Flow Lending |
|---|---|---|
| Sizes off | Eligible collateral (receivables + inventory) × advance rate | EBITDA × leverage multiple |
| Capacity | Capped at the borrowing base | Banks 3–4x, direct lenders 4–5.5x EBITDA (low end for non-sponsored) |
| Flexes with | The working-capital cycle (revolving) | The covenant package, not the daily collateral position |
| 2026 pressure | Tariff-inflated inventory book above appraised value compresses the base | Flows through EBITDA in underwriting, not the availability formula |
| Funds best | Working-capital-cycle needs; seasonal draw | Growth, acquisitions, capex, owner liquidity at $10MM+ consistent EBITDA |
| Right for | EBITDA below ~$10–15MM or cyclically volatile; collateral is the binding constraint | $10MM+ consistent EBITDA; earnings can support more than the collateral allows |
How the Transition Works
Moving from ABL to a cash-flow structure is not exotic. A lender needs two to three years of consistent EBITDA with audited or reviewed financials, a quality-of-earnings analysis, and a negotiated covenant package. From mandate to close, a first-time cash-flow facility for a non-sponsored manufacturer typically runs 30–60 days. And the choice is not always binary. Many manufacturers run both: an ABL revolver for day-to-day working capital alongside a cash-flow term loan — or a unitranche structure — for growth. The revolver handles the cycle; the term loan funds the strategic decisions.
The Ceiling You Don’t See Until You Test It
Picture a manufacturer with steady margins and a diversified customer base, borrowing on an ABL revolver it has had since the business was smaller. The line still covers day-to-day needs. Then it moves to fund an acquisition — and the borrowing base will not stretch. The earnings could easily carry the debt; the collateral pool simply is not large enough to reflect what the business has become.
Test the market, and cash-flow lenders size off EBITDA — well above what the borrowing base allowed. The restructure funds the growth the old line never could. The ceiling was never the business. It was the debt product.
That is the trap: the structure is rarely revisited once it is in place, and no lender volunteers to replace the facility it is earning on. For a profitable manufacturer, the question is worth asking directly — because testing the market is the only way to learn what your earnings can actually support.
